Trial Profile
An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs Ezaladcigene resoparvovec (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Neurocrine Biosciences
- 17 Mar 2022 Status changed from active, no longer recruiting to completed.
- 22 Sep 2021 Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
- 16 Sep 2020 18 months Results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders